Pfizer Inc. now expects to manufacture 80 million treatment courses of the company’s experimental COVID-19 antiviral drug, up from a previous forecast of 50 million, Chief Executive Officer Albert Bourla said in a CNBC interview on November 29.
Novartis agreed to expand the company’s fill-and-finish support for the Pfizer/BioNTech Covid-19 vaccine by using manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022, the Swiss drugmaker said on Oct. 21.
Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.
CureVac said on Sept. 14 the German biotech firm cancelled contract manufacturing deals for the company’s experimental Covid-19 vaccine with two prospective partners, after rivals with approved shots boosted production.
BioNTech and Pfizer will boost manufacturing capacity of their Covid-19 vaccine to 2.5 billion doses by the end of 2021, BioNTech said on March 30, as the company projected sales of nearly 10 billion euros ($11.7 billion) from the product during 2021.
Russia’s Sputnik V could be produced in western Europe for the first time after a deal to make the Covid-19 vaccine in Italy was signed by the RDIF sovereign wealth fund and Swiss-based pharmaceutical company Adienne.
Merck & Co. will help make rival Johnson & Johnson’s Covid-19 vaccine in order to boost the slower-than-promised production of the one-dose shot, U.S. President Joe Biden said on March 2.
The United States expects to roll out 3 to 4 million doses of Johnson & Johnson’s Covid-19 vaccine during the first week of March, pending authorization from the Food and Drug Administration, White House Covid-19 response coordinator Jeff Zients said on Feb. 24.
Merck & Co. Inc. was in talks with governments and companies to potentially help with manufacturing of Covid-19 vaccines that have been already authorized.
The Biden administration is exploring every option for increasing manufacturing of Johnson & Johnson’s Covid-19 vaccine, which is under regulatory review, and said on Feb. 5 that currently expected levels of early doses were less than hoped.